These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19730774)

  • 21. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversity of cytogenetic and pathohistologic profiles in glioblastoma.
    Hassler M; Seidl S; Fazeny-Doerner B; Preusser M; Hainfellner J; Rössler K; Prayer D; Marosi C
    Cancer Genet Cytogenet; 2006 Apr; 166(1):46-55. PubMed ID: 16616111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme.
    Kase M; Vardja M; Lipping A; Asser T; Jaal J
    Radiother Oncol; 2011 Oct; 101(1):127-31. PubMed ID: 21775006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
    Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
    Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.
    Zhang GB; Cui XL; Sui DL; Ren XH; Zhang Z; Wang ZC; Lin S
    J Neurooncol; 2013 Jun; 113(2):251-8. PubMed ID: 23494873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epigenetic regulation in glioblastomas].
    Quillien V
    Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
    [No Abstract]   [Full Text] [Related]  

  • 29. Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy.
    Sonoda Y; Matsumoto K; Kakuto Y; Nishino Y; Kumabe T; Tominaga T; Katakura R
    Acta Neurochir (Wien); 2007 Nov; 149(11):1183-9; discussion 1189. PubMed ID: 17712511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa.
    Krakowczyk L; Strzelczyk JK; Adamek B; Zalewska-Ziob M; Arendt J; Półtorak S; Maciejewski B; Wiczkowski A
    Med Sci Monit; 2008 Oct; 14(10):BR219-25. PubMed ID: 18830187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological findings and prognostic factors in recurrent glioblastomas.
    Okita Y; Narita Y; Miyakita Y; Ohno M; Fukushima S; Kayama T; Shibui S
    Brain Tumor Pathol; 2012 Oct; 29(4):192-200. PubMed ID: 22331317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of p53 protein expression in glioblastoma.
    Birner P; Piribauer M; Fischer I; Gatterbauer B; Marosi C; Ungersböck K; Rössler K; Budka H; Hainfellner JA
    Oncol Rep; 2002; 9(4):703-7. PubMed ID: 12066196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables.
    Yuile P; Dent O; Cook R; Biggs M; Little N
    J Clin Neurosci; 2006 Aug; 13(7):747-51. PubMed ID: 16908158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How I treat glioblastoma in older patients.
    Mohile NA
    J Geriatr Oncol; 2016 Jan; 7(1):1-6. PubMed ID: 26725536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining pseudoprogression in glioblastoma multiforme.
    Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM
    Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
    Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
    Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prime time for molecular marker diagnostics in neuro-oncology.
    Weller M; Stupp R
    Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
    [No Abstract]   [Full Text] [Related]  

  • 40. A silver lining on the horizon for glioblastoma.
    Knisely JP; Baehring JM
    Lancet Oncol; 2009 May; 10(5):434-5. PubMed ID: 19410186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.